1. Home
  2. CFFN vs ABUS Comparison

CFFN vs ABUS Comparison

Compare CFFN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

HOLD

Current Price

$8.80

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.18

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFFN
ABUS
Founded
1893
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
CFFN
ABUS
Price
$8.80
$5.18
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$7.25
$5.00
AVG Volume (30 Days)
711.2K
4.3M
Earning Date
04-29-2026
05-14-2026
Dividend Yield
4.51%
N/A
EPS Growth
79.31
55.26
EPS
0.51
0.84
Revenue
$16,300,000.00
$14,083,000.00
Revenue This Year
$20.16
N/A
Revenue Next Year
$6.62
$239.71
P/E Ratio
$17.25
$6.17
Revenue Growth
6.54
128.21
52 Week Low
$5.97
$3.50
52 Week High
$9.26
$5.45

Technical Indicators

Market Signals
Indicator
CFFN
ABUS
Relative Strength Index (RSI) 53.34 64.76
Support Level $8.43 $4.34
Resistance Level $8.84 $5.42
Average True Range (ATR) 0.13 0.12
MACD 0.02 -0.00
Stochastic Oscillator 71.29 61.97

Price Performance

Historical Comparison
CFFN
ABUS

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: